Bernard Escudier

88.9k total citations · 15 hit papers
717 papers, 41.8k citations indexed

About

Bernard Escudier is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Bernard Escudier has authored 717 papers receiving a total of 41.8k indexed citations (citations by other indexed papers that have themselves been cited), including 599 papers in Pulmonary and Respiratory Medicine, 294 papers in Molecular Biology and 280 papers in Cancer Research. Recurrent topics in Bernard Escudier's work include Renal cell carcinoma treatment (546 papers), Cancer Genomics and Diagnostics (259 papers) and Renal and related cancers (243 papers). Bernard Escudier is often cited by papers focused on Renal cell carcinoma treatment (546 papers), Cancer Genomics and Diagnostics (259 papers) and Renal and related cancers (243 papers). Bernard Escudier collaborates with scholars based in France, United States and Italy. Bernard Escudier's co-authors include Camillo Porta, Alain Ravaud, Sylvie Négrier, Brian I. Rini, Stéphane Oudard, Thomas E. Hutson, Robert J. Motzer, Cezary Szczylik, Christine Chevreau and Ronald M. Bukowski and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Bernard Escudier

701 papers receiving 41.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

2007 3.8k citations Bernard Escudier, Tim Eisen et al. profile →
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

2008 2.3k citations Robert J. Motzer, Bernard Escudier et al. The Lancet profile →
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2014 1.8k citations Bernard Escudier, Camillo Porta et al. profile →
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

2007 1.7k citations Bernard Escudier, A Płużańska et al. The Lancet profile →
Renal cell carcinoma

2009 1.3k citations Brian I. Rini, Bernard Escudier et al. The Lancet profile →
Phase 3 trial of everolimus for metastatic renal cell carcinoma

2010 903 citations Robert J. Motzer, Bernard Escudier et al. profile →
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

2009 864 citations Bernard Escudier, Tim Eisen et al. Journal of Clinical Oncology profile →
Malignant effusions and immunogenic tumour-derived exosomes

2002 793 citations Bernard Escudier, Eric Angevin et al. The Lancet profile →
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2019 774 citations Bernard Escudier, Camillo Porta et al. profile →
Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

1998 742 citations Sylvie Négrier, Bernard Escudier et al. profile →
Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

2010 632 citations Bernard Escudier, Joaquim Bellmunt et al. Journal of Clinical Oncology profile →
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

2018 631 citations Laurence Albigès, Bernard Escudier et al. profile →
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

2013 542 citations Robert J. Motzer, Bernard Escudier et al. profile →
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2016 388 citations Bernard Escudier, Camillo Porta et al. profile →
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

2022 177 citations Robert J. Motzer, Thomas Powles et al. profile →

Peers

Countries citing papers authored by Bernard Escudier

Since Specialization

Citations

This map shows the geographic impact of Bernard Escudier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernard Escudier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernard Escudier more than expected).

Fields of papers citing papers by Bernard Escudier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernard Escudier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernard Escudier. The network helps show where Bernard Escudier may publish in the future.

Co-authorship network of co-authors of Bernard Escudier

This figure shows the co-authorship network connecting the top 25 collaborators of Bernard Escudier. A scholar is included among the top collaborators of Bernard Escudier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernard Escudier. Bernard Escudier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association of Corticosteroids With Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab 2023 ·JAMA Oncology ·(unknown), Cécile Dalban, Marine Gross‐Goupil, Brigitte Laguerre, Sylvie Chabaud, Bernard Escudier, Laurence Albigès	4
2	Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer 2022 ·Clinical Genitourinary Cancer ·Zeynep Büşra Zengin, Sumanta K. Pal, David F. McDermott, Bernard Escudier, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael B. Atkins, Vijay Kasturi, Brian I. Rini	3
3	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. 2022 ·Apollo (University of Cambridge) ·Bhavna Oza, Tim Eisen, Eleni Frangou, Grant D. Stewart, Axel Bex, A.W.S. Ritchie, Richard Kaplan, (unknown), Ian D. Davis, Martin R. Stockler, Laurence Albigès, Bernard Escudier, James Larkin, Steven Joniau, Barry W. Hancock, Gregers G. Hermann, Joaquim Bellmunt, Mahesh Parmar, Patrick Royston, Angela Meade	10
4	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial 2020 ·European Urology ·Brian I. Rini, Robert J. Motzer, Thomas Powles, David F. McDermott, Bernard Escudier, Frede Donskov, Robert D. Hawkins, Sergio Bracarda, Jens Bedke, Ugo De Giorgi, Camillo Porta, Alain Ravaud, Francis Parnis, Enrique Grande, Wei Zhang, Mahrukh Huseni, Susheela Carroll, Roxana I. Sufan, Christina Schiff, Michael B. Atkins	60
5	Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis 2018 ·Clinical Cancer Research ·Daniel J. George, Jean-François Martini, Michael Staehler, Robert J. Motzer, Ahmed Magheli, Frede Donskov, Bernard Escudier, Sherry Li, Michelle Casey, Olga Valota, Brigitte Laguerre, Allan J. Pantuck, Hardev Pandha, Anup Patel, (unknown), Alain Ravaud	18
6	Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib 2018 ·Clinical Cancer Research ·Brian I. Rini, Bernard Escudier, Jean-François Martini, Ahmed Magheli, Christer Svedman, Margarita Lopatin, Dejan Knezevic, Audrey D. Goddard, Phillip G. Febbo, Rachel Li, Xun Lin, Olga Valota, Michael Staehler, Robert J. Motzer, Alain Ravaud	45
7	Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial 2018 ·Journal of Clinical Oncology ·Bernard Escudier, Thomas Powles, Robert J. Motzer, Thomas Olencki, Osvaldo Arén Frontera, Stéphane Oudard, Frédéric Rolland, Piotr Tomczak, Daniel Castellano, Leonard J. Appleman, Harry A. Drabkin, Daniel A. Vaena, Steven Milwee, (unknown), Julie C. Lougheed, Sergio Bracarda, Toni K. Choueiri	121
8	Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial 2017 ·European Journal of Cancer ·Patrick Schöffski, Agnieszka Woźniak, Bernard Escudier, Piotr Rutkowski, Alan Anthoney, Sebastian Bauer, Jozef Šufliarský, Carla van Herpen, Lars H. Lindner, Viktor Grünwald, Branko Zakotnik, Evelyne Lerut, Maria Dêbiec‐Rychter, Sandrine Marréaud, Michela Lia, Tiana Raveloarivahy, Sandra Collette, Laurence Albigès	94
9	Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer 2014 ·Clinical Cancer Research ·Bernard Escudier, Viktor Grünwald, Alain Ravaud, Yen‐Chuan Ou, Daniel Castellano, Chia‐Chi Lin, Jürgen E. Gschwend, Andrea Harzstark, (unknown), Nicoletta Pirotta, Matthew Squires, Michael Shi, Eric Angevin	49
10	MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array 2014 ·Clinical Cancer Research ·Laurence Albigès, Justine Guégan, Audrey Le Formal, Virginie Verkarre, Nathalie Rioux‐Leclercq, Mathilde Sibony, Jean‐Christophe Bernhard, Philippe Camparo, (unknown), Vincent Molinié, Yves Allory, Cédric Oréar, Sophie Couvé, Sophie Gad, Jean‐Jacques Patard, Bernard Escudier	134
11	Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes 2014 ·Clinical Cancer Research ·Gabriel G. Malouf, Xiaoping Su, Hui Yao, Jianjun Gao, Liangwen Xiong, Qiuming He, Éva Compérat, Jérôme Couturier, Vincent Molinié, Bernard Escudier, Philippe Camparo, (unknown), Erika J. Thompson, David Khayat, Christopher G. Wood, Willie Yu, Bin Tean Teh, John N. Weinstein, Nizar M. Tannir	97
12	Genomic Heterogeneity of Translocation Renal Cell Carcinoma 2013 ·Clinical Cancer Research ·Gabriel G. Malouf, Federico A. Monzon, Jérôme Couturier, Vincent Molinié, Bernard Escudier, Philippe Camparo, Xiaoping Su, Hui Yao, Pheroze Tamboli, Dolores López‐Terrada, Maria M. Picken, (unknown), Asha S. Multani, Sen Pathak, Christopher G. Wood, Nizar M. Tannir	61
13	Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma 2013 ·Clinical Cancer Research ·Eric Angevin, José A. López-Martín, Chia‐Chi Lin, Jürgen E. Gschwend, Andrea Harzstark, Daniel Castellano, Jean‐Charles Soria, Paramita Sen, Julie Chang, Michael Shi, Andrea Kay, Bernard Escudier	103
14	Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group 2011 ·Clinical Cancer Research ·Judith Manola, Patrick Royston, Paul Elson, (unknown), Madhu Mazumdar, Sylvie Négrier, Bernard Escudier, Tim Eisen, Janice P. Dutcher, Michael B. Atkins, Daniel Yick Chin Heng, Toni K. Choueiri, Robert J. Motzer, Ronald M. Bukowski	148
15	Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial breakdown → 2009 ·Journal of Clinical Oncology ·Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik, Stéphane Oudard, Michael Staehler, Sylvie Négrier, Christine Chevreau, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sibyl Anderson, (unknown), Minghua Shan, Carol Peña, Chetan Lathia, Ronald M. Bukowski	864
16	A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma 2009 ·Clinical Cancer Research ·Chrystelle Brignone, Bernard Escudier, Caroline Grygar, Manon Marcu, Frédéric Triebel	178
17	Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma 2009 ·Journal of Clinical Oncology ·Bernard Escudier, Cezary Szczylik, Thomas E. Hutson, Tomasz Demkow, Michael Staehler, Frédéric Rolland, Sylvie Négrier, Nicole Laferriere, Urban Scheuring, David Cella, Sonalee Shah, Ronald M. Bukowski	378
18	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial breakdown → 2008 ·The Lancet ·Robert J. Motzer, Bernard Escudier, Stéphane Oudard, Thomas E. Hutson, Camillo Porta, Sergio Bracarda, Viktor Grünwald, John A. Thompson, Robert A. Figlin, Norbert Hollaender, Gladys Urbanowitz, William J. Berg, Andrea Kay, David Lebwohl, Alain Ravaud	2339
19	Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma 2007 ·Journal of Clinical Oncology ·Toni K. Choueiri, A. Plantade, Paul Elson, Sylvie Négrier, Alain Ravaud, Stéphane Oudard, Ming Zhou, Brian I. Rini, Ronald M. Bukowski, Bernard Escudier	311
20	Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial breakdown → 2007 ·The Lancet ·Bernard Escudier, A Płużańska, P. Koralewski, Alain Ravaud, Sergio Bracarda, Cezary Szczylik, Christine Chevreau, M. Filipek, Bohuslav Melichar, Emilio Bajetta, В. А. Горбунова, Jacques‐Olivier Bay, I. Bodrogi, Agnieszka Jagiełło-Gruszfeld, N. Moore	1722

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact